PUMA BIOTECHNOLOGY, INC. Research And Development Expense

• PUMA BIOTECHNOLOGY, INC. showed a decrease of -26.4% in Research And Development Expense from 2020 to 2021.
• This data is from PUMA BIOTECHNOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2022.
• XBRL data for this metric is available from 2011 to 2021 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2012: $10.57 million | Q2 2012: $13.01 million | Q3 2012: $17.78 million | Q1 2013: $9.53 million | Q2 2013: $10.44 million | Q3 2013: $12.07 million | Q1 2014: $16.29 million | Q2 2014: $35.00 million | Q3 2014: $32.09 million | Q1 2015: $44.73 million | Q2 2015: $59.38 million | Q3 2015: $51.92 million | Q1 2016: $60.21 million | Q2 2016: $54.22 million | Q3 2016: $51.98 million | Q1 2017: $54.80 million | Q2 2017: $53.25 million | Q3 2017: $49.50 million | Q1 2018: $46.93 million | Q2 2018: $43.25 million | Q3 2018: $36.36 million | Q1 2019: $35.73 million | Q2 2019: $36.86 million | Q3 2019: $30.03 million | Q1 2020: $25.46 million | Q2 2020: $24.69 million | Q3 2020: $23.34 million | Q1 2021: $20.23 million | Q2 2021: $18.64 million | Q3 2021: $18.84 million | Q1 2022: $15.24 million | Q2 2022: $11.97 million.
• Over the full 11 years of available data (2011 to 2021), PUMA BIOTECHNOLOGY, INC.'s Research And Development Expense has grown by 8,601.0%.
• Historical annual values: Fiscal year 2021: $71.87 million | Fiscal year 2020: $97.65 million | Fiscal year 2019: $132.85 million | Fiscal year 2018: $164.85 million | Fiscal year 2017: $207.81 million | Fiscal year 2016: $222.80 million | Fiscal year 2015: $208.47 million | Fiscal year 2014: $122.92 million | Fiscal year 2013: $45.05 million | Fiscal year 2012: $49.64 million | Fiscal year 2011: $826.0 thousand.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026